Our observation that KMT2D is more commonly mutated in BRCA2d suggests that it plays a role in BRCA2-associated prostate carcinogenesis and may identify therapeutic targets for BRCA2d prostate cancer. This evidence concerns the gene BRCA2 and urogenital neoplasm.